CareDx (NASDAQ: CDNA) reported Q4 EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $35.8 million versus the consensus estimate of $35.78 million.

"We are very pleased with our fourth quarter and 2019 annual financial results," said Peter Maag, CareDx Chief Executive Officer. "2019 was an exceptional year for CareDx, as we continued to build an incredible moat in Transplantation. With AlloSure and AlloMap, we impact more transplant patients every day. With our transplant focused clinical activities and our pipeline advancing, our platform is promising to deliver continued stellar growth."

For earnings history and earnings-related data on CareDx (CDNA) click here.